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gamma knife, one fractionated stereotactic radiotherapy (SRT) by 
linac, and 9 conventionally-fractionated 3-dimensional conformal 
radiotherapies (3DCRTs). All but one patient had gross residual or 
recurrent tumor at the time of radiotherapy. Median doses were 18 Gy 
(range: 12-20 Gy) at tumor margin for SRS, and 60 Gy (range: 54-60 
Gy) for 3DCRT. SRT dose was 36 Gyin 6 fractions at isocenter. 
Results: Intracranial recurrences were observed after 28 treatment 
sessions in 20 patients, and 9 patients died with a median follow-up of 
17.7 months (range: 2-65 months). Local control rates at 1 year and 2 
years were 60.9% and 22.2%, respectively. Atypical hisotologies and 
higher dose treatments (BED3> 125Gy) appeared better local control, 
but the differences were not statistically significant (p values were 
0.072 and 0.097 respectively). Among 5 patients with intracranial 
recurrences after linac radiotherapy, 4 patients had recurrences from 
high dose regions, and marginal recurrence was seen in another 
patient. Among 23 recurrent patients with gamma knife, 2, 6, and 9 
patients experienced central, marginal, and distant recurrences, and 
data on recurrence sites were not available in other 6 patients. The 
patterns of recurrence were significantly different between linac and 
gamma knife groups (p=0.006). 
Conclusions: Our data suggested that it require high dose to the gross 
tumor and prophylactic dose around the tumor for a good local control 
of atypical or anaplasitc meningioma. Treatment results might be 
improved by combined treatment strategy of 3DCRT and stereotactic 
irradiation boost for atypical and anaplasitc meningiomas. 
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Purpose/Objective: TBI is an important part of conditioning regimens 
in patients undergoing hematopoietic cell transplantation (HCT). IMRT 
coupled with image-guided radiation therapy produces highly 
conformal dose distributions in the target volumes and reduces the 
dose to critical organs. We will plan IMRT for TBI to quantify the 
dosimetric gains when compared to traditional techniques. 
Materials and Methods: Four patients treated at our institution were 
chosen and 4 patients’ head-to-thigh computed tomographic images 
were used in this study. We defined the target as the body volume 
without the total lung and kidneys for myeloablative regimens and the 
body volume for nonmyeloablative and reduced intensity regimens. A 
traditional 3D plan along with an IMRT plan was computed for each 
patient. The planned doses were 2Gy/1fr., 12Gy/6fr., 4Gy/2fr. and 
4Gy/2fr.. The traditional and the IMRT techniques used opposed 
lateral fields and helical tomotherapy, respectively. 
Results: Homogeneity index (HI) was 0.12 (range, 0.07-0.20) for IMRT 
plans and 0.34 (range, 0.25-0.40) for traditional 3D plans. The total 
lung and kidney average doses were 8.1Gy and 10.4Gy, respectively, 
for IMRT plan and 10.3Gy and 11.7Gy, respectively, for a traditional 
plan in myeloablative regimens. 
Conclusions: IMRT for TBI has a dosimetric advantage in both target 
coverage and critical organ sparing over traditional beam 
arrangement. 
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Purpose/Objective: To determine the efficacy of Whole Brain 
Radiotherapy (WBRT) with carboplatin as radiation sensitizer in 
metastatic brain disease in our adult population. 
Materials and Methods: Forty two patients with metastatic brain 
disease having ECOG performance status (PS) 3 or less with normal 
haematological and biochemical profile were treated with WBRT with 
6MV Photon beam on linear accelerator using parallel opposed lateral 
beams to a dose of 30 Gys in 10 fractions. Carboplatin was 
administered in a dose of 150 mg/m2 on day 1 and 6 of WBRT. 
Improvement in PS and radiological response on CT scan/MRI brain 
before and 30 days after the WBRT using RECIST criteria was 
evaluated. 
Results: Out of 42 patients, 38 (90%) showed improvement in PS, 4 
(10%) showed either no improvement or worsening of PS (p ? 0.001). 
Seventeen (41%) patients had complete response,19 (45%) had partial 
response, 3 (7%) showed stable disease and 3 (7%) had progressive 
disease. None of the patient showed grade 3/4 toxicity during 
treatment. 
Conclusions: WBRT with carboplatin as radiation sensitizer is 
effective in palliation of patients with metastatic brain disease. Large 
scale randomised controlled trials are needed before making changes 
in routine clinical practice. 
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Purpose/Objective: Head and neck patients have been treated with 
IMRT in the radiotherapy department of our hospital since 2007, after 
a complete renewal of equipment. In a first phase direct planning has 
been used followed by inverse optimization after the learning curve 
has attained stability. ICRU 83 recommendations have been smoothly 
incorporated. During this period the registration process for treatment 
outcome assessment has also been restructured with the development 
of a digital platform enabling the comprehensive registration of both 
early and late effects and tumour response parameters. An overview 
of the clinical results that were electronically recorded in this 
platform since the middle of 2011 will be presented. 
Materials and Methods: From the treated patients the response to RT 
of 268 has already been documented in the electronic RT health 
system. Tumour cases were divided as: larynx (21.3%); oropharynx 
(20.9%); oral cavity (18.3%); nasopharynx (14.6%); hypopharynx (8.6%); 
pharyngeal-laryngeal (8.6%) and other pathology (7.8%). Mean age was 
57±12.6 years and mean prescribed dose was 65.6±4.9Gy. Direct 
optimization was used in 31.6% of the clinical cases and inverse IMRT 
in 50.4%. The remaining 18% corresponded to simpler clinical cases 
where 3D-CRT with less than 10 beam incidences have been sufficient 
to reach the treatment objectives in terms of conformality. The mean 
follow-up was 8 months (ranging from 0 days to 5 years) corresponding 
to a weekly periodicity during treatment followed by 3 monthly 
spaced visits during 2 years and then every 6 months. Complications 
for salivary glands, mucous membrane, esophagus, larynx, pharynx, 
mandible, skin, pain, ear, teeth and weight loss were reported 
through the digital platform on the basis of RTOG and CTCAE v3.0 
guidelines. 
Results: For a follow-up of 24 months in patients with stage I,II 
(19.4%) and III,IV (80.6%) local regional control was 86%, was disease 
free survival was 86% and 79% and overall survival rate was 100% and 
84%, respectively. For salivary glands no complications with grade (G) 
larger than 2 were reported. Maximum incidence of G2 complications 
was 41% for the seventh week of treatment which was reduced to 
12%for a follow-up of 2 years. Mucositis was reported with G2 and G3 
mostly during treatment (46%) that prevailed 6 months after 
treatment just for 4 patients (9%). Time evolution of esophagus, 
larynx and pharynx complications showed a similar pattern with just 
residual G3 cases and with G2 maximum incidence at the end of the 
treatment.  
Conclusions: The electronic patient information system developed 
and in use clinically is a very useful tool during the medical 
appointment for fast and systematic registration of patient response 
to RT. The comprehensive nature of this database enabled easy 
statistical assessment of patient treatment outcome and has further 
potentialities for radiobiological studies. 
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Purpose/Objective: To study the effect of HDR Interstitial 
Brachytherapy boost to EBRT in early stage T1/T2 and with concurrent 
chemoradiotherapy in T1 to T3 with N1/N2a/N2b or T3N0 squamous 
cell carcinoma of buccal mucosa, anterior 2/3rdtongue and floor of 
mouth in local control in adults as very few trials and review 
literatures have been reported in this. 
